Back to search results

Phase 2 Study of LTI-03 for Idiopathic Pulmonary Fibrosis

This study is testing an experimental medication called LTI-03 for people with Idiopathic Pulmonary Fibrosis (IPF), a serious lung disease that causes scarring and breathing problems. LTI-03 is breathed in using an inhaler and is thought to help protect lung cells and reduce scarring. Researchers want to see if LTI-03 is safe, what side effects it might cause, and if it improves lung scarring and IPF symptoms. You may be able to join if you are 40 years or older, have been diagnosed with IPF within the last 5 years, and meet other specific criteria. The study plans to enroll about 120 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 120 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and tolerability will be measured from Day 1 through Week 24 after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06968845

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Recruiting
PHASE2Ages 40+InterventionalTreatment
Rein Therapeutics
~120 participants
Updated 2026-09-04 on ClinicalTrials.gov
What's tested:LTI-03Dry Powder InhalerPlacebo

At a glance

Recruiting sites
36 of 36 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs)
Measured over Day 1 through Week 24

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Explore related trials

Idiopathic Pulmonary Fibrosis

NCT06968845

Where you'd take part

This study runs at 36 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Agaplesion Evangelisches Krankenhaus Mittelhessen

    Giessen, Hesse, Germanystudy coordinator listed

    Recruiting

  • Baylor College of Medicine

    Houston, Texasstudy coordinator listed

    Recruiting

  • Baylor Scott and White Health

    Temple, Texasstudy coordinator listed

    Recruiting

  • Birmingham Chest Clinic

    Birmingham, Birmingham, United Kingdomstudy coordinator listed

    Recruiting

  • Box Hill Hospital

    Box Hill, Victoria, Australiastudy coordinator listed

    Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, Californiastudy coordinator listed

    Recruiting

  • Churchill Hospital

    Oxford, Oxfordshire, United Kingdomstudy coordinator listed

    Recruiting

  • Cleveland Clinic Florida

    Weston, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Steven A. Shoemaker, MD
[email protected]
720-560-2167
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs)Day 1 through Week 24